Hey all, welcome back to the real-life pharmacology podcast. I'm your host pharmacist, Derek Christensen. Thank you so much for listening today. As always, go check out the free top 200 study guide, a 31-page PDF on some of the most important things that you're going to be tested on, as well as some of the most important things that show up in clinical practice on the top 200 drugs. So absolutely free to do simply an email.

We'll get you access.

We get you updates.

Well, we've got new podcasts and other content available as well.

All right.

Let's get into number 161 through 165.

So we've got Laraglutide.

I've also heard of pronounce Liraglutide, probably Laraglutide. I've also heard it pronounced Liraglutide.

Probably Laraglutide is the most common pronunciation I've heard.

Brand name is Victoza.

There's also another product, Saxenda, which is a little bit higher dose.

And the indication for this medication is diabetes.

And then for Saccenda, that is for weight management or weight loss.

Mechanistically, this is a GLP1 agonist as its classification.

It is a glucagon like peptide one agonist that enhances

glucose-dependent insulin secretion, slows down that gastric emptying, and ultimately

helps reduce post-pranthial blood sugars. Okay.

So those are those blood sugars after we eat.

So that's really its major target when we're using it for diabetes. And obviously with weight management, the promotion of that fullness feeling, the slowing of the gastric emptying. That's what can really help patients eat

less and lose weight. Adverse effect profile, the way I kind of think about is if you think about

slowing down the gut, more food sitting in there for a longer period of time. That can cause some issues with nausea.

In particular, even, you know, some case a little bit more severe where we have some

...